 Kevin Lillehei
Concepts (605)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Brain Neoplasms | 48 | 2023 | 979 | 3.580 |
Why?
| | Pituitary Neoplasms | 26 | 2020 | 157 | 2.860 |
Why?
| | Adenoma | 21 | 2020 | 189 | 2.430 |
Why?
| | Meningioma | 12 | 2022 | 77 | 2.120 |
Why?
| | Glioblastoma | 18 | 2023 | 253 | 1.830 |
Why?
| | Pituitary Gland | 11 | 2020 | 148 | 1.830 |
Why?
| | Central Nervous System Cysts | 3 | 2020 | 11 | 1.720 |
Why?
| | Neoplasm Recurrence, Local | 19 | 2022 | 858 | 1.610 |
Why?
| | Meningeal Neoplasms | 6 | 2022 | 87 | 1.410 |
Why?
| | Neurosurgical Procedures | 10 | 2021 | 152 | 1.370 |
Why?
| | Peripheral Nervous System Neoplasms | 6 | 2009 | 20 | 1.170 |
Why?
| | Glioma | 15 | 2020 | 294 | 1.040 |
Why?
| | Central Nervous System Neoplasms | 7 | 2017 | 126 | 1.030 |
Why?
| | Radiotherapy, Intensity-Modulated | 5 | 2016 | 124 | 0.920 |
Why?
| | Sphenoid Bone | 2 | 2016 | 15 | 0.910 |
Why?
| | Gliosarcoma | 5 | 2006 | 8 | 0.900 |
Why?
| | Cysts | 3 | 2020 | 93 | 0.820 |
Why?
| | Carmustine | 3 | 2017 | 47 | 0.760 |
Why?
| | Cancer Vaccines | 5 | 2018 | 137 | 0.750 |
Why?
| | Pituitary ACTH Hypersecretion | 2 | 2018 | 9 | 0.750 |
Why?
| | Neoplasms, Radiation-Induced | 4 | 2008 | 67 | 0.740 |
Why?
| | Hypopituitarism | 1 | 2020 | 15 | 0.700 |
Why?
| | Rhabdoid Tumor | 3 | 2010 | 80 | 0.690 |
Why?
| | Radiotherapy, Adjuvant | 2 | 2016 | 182 | 0.640 |
Why?
| | Antibiotics, Antineoplastic | 1 | 2019 | 109 | 0.630 |
Why?
| | Magnetic Resonance Imaging | 29 | 2022 | 3046 | 0.630 |
Why?
| | Immunotherapy | 4 | 2006 | 474 | 0.630 |
Why?
| | Adult | 70 | 2021 | 30544 | 0.610 |
Why?
| | Polyesters | 2 | 2017 | 64 | 0.610 |
Why?
| | Middle Aged | 71 | 2021 | 26733 | 0.600 |
Why?
| | Decanoic Acids | 1 | 2017 | 7 | 0.600 |
Why?
| | Bleomycin | 1 | 2019 | 228 | 0.600 |
Why?
| | Aged | 52 | 2021 | 19069 | 0.550 |
Why?
| | Orbital Diseases | 1 | 2016 | 25 | 0.540 |
Why?
| | Male | 84 | 2021 | 55583 | 0.500 |
Why?
| | Humans | 121 | 2023 | 114662 | 0.480 |
Why?
| | Female | 81 | 2021 | 59493 | 0.470 |
Why?
| | Antineoplastic Agents | 5 | 2017 | 1879 | 0.440 |
Why?
| | Biomarkers, Tumor | 8 | 2017 | 1040 | 0.420 |
Why?
| | Brachial Plexus | 3 | 2007 | 28 | 0.420 |
Why?
| | Retrospective Studies | 26 | 2022 | 12546 | 0.420 |
Why?
| | Immunotherapy, Adoptive | 5 | 1997 | 184 | 0.410 |
Why?
| | Dacarbazine | 7 | 2015 | 99 | 0.400 |
Why?
| | Cisplatin | 3 | 1998 | 262 | 0.390 |
Why?
| | Chemoradiotherapy | 4 | 2015 | 188 | 0.390 |
Why?
| | Skull Neoplasms | 4 | 2012 | 22 | 0.380 |
Why?
| | Craniopharyngioma | 3 | 2020 | 65 | 0.380 |
Why?
| | Cautery | 1 | 2010 | 3 | 0.360 |
Why?
| | Antineoplastic Agents, Alkylating | 5 | 2013 | 68 | 0.350 |
Why?
| | Epithelioid Cells | 1 | 2010 | 8 | 0.350 |
Why?
| | Monosomy | 1 | 2010 | 10 | 0.350 |
Why?
| | Sella Turcica | 5 | 2018 | 13 | 0.350 |
Why?
| | Astrocytoma | 5 | 2014 | 108 | 0.340 |
Why?
| | Chromosomes, Human, Pair 22 | 1 | 2010 | 38 | 0.340 |
Why?
| | Neurosurgery | 2 | 2021 | 26 | 0.340 |
Why?
| | Combined Modality Therapy | 11 | 2016 | 1121 | 0.340 |
Why?
| | Fibromatosis, Aggressive | 2 | 2007 | 17 | 0.330 |
Why?
| | Chromosomal Proteins, Non-Histone | 1 | 2010 | 100 | 0.330 |
Why?
| | Hemangioma | 1 | 2009 | 41 | 0.330 |
Why?
| | Membrane Proteins | 2 | 2017 | 1018 | 0.320 |
Why?
| | In Situ Hybridization, Fluorescence | 6 | 2010 | 309 | 0.320 |
Why?
| | Sarcoma, Ewing | 1 | 2009 | 64 | 0.310 |
Why?
| | Spinal Nerve Roots | 2 | 2006 | 28 | 0.290 |
Why?
| | DNA Mutational Analysis | 3 | 2014 | 372 | 0.290 |
Why?
| | Fibromatosis, Abdominal | 1 | 2007 | 3 | 0.290 |
Why?
| | Young Adult | 14 | 2020 | 10466 | 0.290 |
Why?
| | Immunohistochemistry | 13 | 2011 | 1629 | 0.280 |
Why?
| | Tumor Cells, Cultured | 7 | 2017 | 849 | 0.280 |
Why?
| | Prolactinoma | 3 | 2019 | 11 | 0.280 |
Why?
| | Diagnosis, Differential | 8 | 2010 | 1342 | 0.270 |
Why?
| | Neoplasms | 5 | 2013 | 2097 | 0.270 |
Why?
| | Brachial Plexus Neuropathies | 1 | 2006 | 10 | 0.260 |
Why?
| | Transforming Growth Factor beta2 | 1 | 2006 | 31 | 0.260 |
Why?
| | Ethanol | 1 | 2010 | 538 | 0.260 |
Why?
| | Oligonucleotides, Antisense | 1 | 2006 | 100 | 0.260 |
Why?
| | Growth Hormone-Secreting Pituitary Adenoma | 2 | 2017 | 11 | 0.260 |
Why?
| | Gonadotrophs | 5 | 2015 | 21 | 0.260 |
Why?
| | Proto-Oncogene Proteins c-kit | 1 | 2006 | 63 | 0.260 |
Why?
| | Gene Expression Regulation, Neoplastic | 8 | 2017 | 1141 | 0.250 |
Why?
| | Postoperative Complications | 8 | 2018 | 2128 | 0.250 |
Why?
| | Treatment Outcome | 12 | 2020 | 9088 | 0.250 |
Why?
| | Adolescent | 20 | 2020 | 17841 | 0.250 |
Why?
| | Rats, Inbred F344 | 7 | 2006 | 241 | 0.240 |
Why?
| | Interleukin-2 | 6 | 1997 | 413 | 0.240 |
Why?
| | DNA-Binding Proteins | 2 | 2010 | 1314 | 0.240 |
Why?
| | Oligonucleotide Array Sequence Analysis | 7 | 2015 | 740 | 0.240 |
Why?
| | Hemangioblastoma | 1 | 2004 | 3 | 0.230 |
Why?
| | Neoplasms, Second Primary | 4 | 2012 | 92 | 0.230 |
Why?
| | Adrenocorticotropic Hormone | 1 | 2004 | 128 | 0.220 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 5 | 2015 | 1355 | 0.220 |
Why?
| | Transcription Factors | 2 | 2010 | 1528 | 0.220 |
Why?
| | Neurologic Examination | 3 | 2019 | 114 | 0.220 |
Why?
| | Cauda Equina | 2 | 2004 | 7 | 0.220 |
Why?
| | Inappropriate ADH Syndrome | 2 | 2018 | 7 | 0.210 |
Why?
| | Drug Implants | 3 | 2017 | 70 | 0.210 |
Why?
| | Postoperative Period | 3 | 2020 | 289 | 0.210 |
Why?
| | Tumor Suppressor Protein p53 | 4 | 2012 | 445 | 0.210 |
Why?
| | Motor Cortex | 1 | 2003 | 47 | 0.210 |
Why?
| | Pancreatic Neoplasms | 1 | 2009 | 731 | 0.210 |
Why?
| | T-Lymphocytes, Cytotoxic | 3 | 2000 | 154 | 0.200 |
Why?
| | Prognosis | 10 | 2021 | 3329 | 0.200 |
Why?
| | Pituitary Diseases | 3 | 2017 | 22 | 0.200 |
Why?
| | Prospective Studies | 11 | 2023 | 6219 | 0.190 |
Why?
| | Fistula | 1 | 2022 | 26 | 0.190 |
Why?
| | Follow-Up Studies | 8 | 2017 | 4411 | 0.190 |
Why?
| | Intracranial Hypotension | 1 | 2022 | 16 | 0.190 |
Why?
| | Proto-Oncogene Proteins B-raf | 2 | 2014 | 192 | 0.190 |
Why?
| | Frontal Bone | 2 | 2015 | 13 | 0.190 |
Why?
| | Pineal Gland | 1 | 2021 | 13 | 0.190 |
Why?
| | Pinealoma | 1 | 2021 | 11 | 0.190 |
Why?
| | Aspergillus | 2 | 2013 | 16 | 0.190 |
Why?
| | Neoplasms, Multiple Primary | 2 | 2016 | 52 | 0.190 |
Why?
| | Ki-67 Antigen | 4 | 2011 | 103 | 0.180 |
Why?
| | Neuropathology | 1 | 2020 | 3 | 0.180 |
Why?
| | Telepathology | 1 | 2020 | 3 | 0.180 |
Why?
| | Tomography, X-Ray Computed | 12 | 2022 | 2285 | 0.180 |
Why?
| | Radiosurgery | 3 | 2010 | 299 | 0.180 |
Why?
| | Reactive Oxygen Species | 2 | 2000 | 531 | 0.180 |
Why?
| | Paraneoplastic Endocrine Syndromes | 1 | 2000 | 1 | 0.180 |
Why?
| | Esthesioneuroblastoma, Olfactory | 1 | 2000 | 1 | 0.180 |
Why?
| | Stereotaxic Techniques | 1 | 2020 | 29 | 0.170 |
Why?
| | Survival Analysis | 7 | 2018 | 1211 | 0.170 |
Why?
| | Extracellular Vesicles | 1 | 2021 | 83 | 0.170 |
Why?
| | Fluorescein | 1 | 2020 | 25 | 0.170 |
Why?
| | Paranasal Sinus Neoplasms | 1 | 2000 | 17 | 0.170 |
Why?
| | Lung Neoplasms | 3 | 2013 | 2177 | 0.170 |
Why?
| | Nose Neoplasms | 1 | 2000 | 15 | 0.170 |
Why?
| | Salivary Glands | 1 | 2020 | 31 | 0.170 |
Why?
| | Aged, 80 and over | 12 | 2020 | 6345 | 0.170 |
Why?
| | Neoplasm Grading | 2 | 2017 | 242 | 0.160 |
Why?
| | Genes, Tumor Suppressor | 2 | 2017 | 77 | 0.160 |
Why?
| | Dendritic Cells | 2 | 2023 | 435 | 0.160 |
Why?
| | Sphenoid Sinusitis | 1 | 2018 | 4 | 0.160 |
Why?
| | Survival Rate | 6 | 2015 | 1644 | 0.160 |
Why?
| | Chemotherapy, Adjuvant | 5 | 2015 | 332 | 0.160 |
Why?
| | Time Factors | 10 | 2011 | 6114 | 0.160 |
Why?
| | Stroke | 2 | 2021 | 1022 | 0.160 |
Why?
| | Polyethylenes | 1 | 2018 | 15 | 0.160 |
Why?
| | Hemangioma, Cavernous | 1 | 1998 | 14 | 0.160 |
Why?
| | ErbB Receptors | 4 | 2006 | 554 | 0.160 |
Why?
| | Oligodendroglioma | 2 | 2014 | 15 | 0.160 |
Why?
| | Adenocarcinoma | 2 | 2004 | 795 | 0.160 |
Why?
| | Endocrine Glands | 1 | 1998 | 15 | 0.160 |
Why?
| | International Educational Exchange | 1 | 2018 | 11 | 0.160 |
Why?
| | Sphenoid Sinus | 1 | 2018 | 8 | 0.150 |
Why?
| | Antioxidants | 2 | 2000 | 530 | 0.150 |
Why?
| | Mutation | 3 | 2014 | 3345 | 0.150 |
Why?
| | Hyponatremia | 1 | 2018 | 37 | 0.150 |
Why?
| | Rats | 8 | 2006 | 4958 | 0.150 |
Why?
| | Remission Induction | 1 | 2018 | 233 | 0.150 |
Why?
| | Cerebrovascular Disorders | 1 | 1998 | 82 | 0.150 |
Why?
| | Contraceptives, Oral, Hormonal | 1 | 2017 | 23 | 0.150 |
Why?
| | Reoperation | 5 | 2020 | 514 | 0.150 |
Why?
| | Quinazolines | 2 | 2010 | 240 | 0.140 |
Why?
| | Students, Medical | 1 | 2021 | 262 | 0.140 |
Why?
| | Prostheses and Implants | 1 | 2018 | 137 | 0.140 |
Why?
| | Transcriptome | 2 | 2020 | 725 | 0.140 |
Why?
| | Thalamic Diseases | 1 | 2017 | 3 | 0.140 |
Why?
| | Desmosomes | 1 | 2017 | 20 | 0.140 |
Why?
| | Xanthomatosis | 1 | 2017 | 10 | 0.140 |
Why?
| | Third Ventricle | 1 | 2017 | 14 | 0.140 |
Why?
| | Cell Proliferation | 5 | 2015 | 2186 | 0.140 |
Why?
| | Exophthalmos | 1 | 2016 | 19 | 0.140 |
Why?
| | Cytokines | 2 | 2021 | 1840 | 0.140 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2004 | 961 | 0.130 |
Why?
| | Brain Injuries | 1 | 2021 | 461 | 0.130 |
Why?
| | Progesterone | 1 | 2017 | 232 | 0.130 |
Why?
| | Antigens, Neoplasm | 2 | 2013 | 222 | 0.130 |
Why?
| | Glycoproteins | 3 | 2012 | 304 | 0.130 |
Why?
| | Receptors, Somatostatin | 1 | 2015 | 24 | 0.130 |
Why?
| | Neurothekeoma | 1 | 1995 | 4 | 0.130 |
Why?
| | Occipital Lobe | 2 | 2006 | 23 | 0.130 |
Why?
| | Tibial Nerve | 1 | 1995 | 10 | 0.130 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2015 | 69 | 0.130 |
Why?
| | Genes, p53 | 2 | 2011 | 61 | 0.120 |
Why?
| | Molecular Chaperones | 2 | 2013 | 157 | 0.120 |
Why?
| | Biocompatible Materials | 1 | 2018 | 369 | 0.120 |
Why?
| | Accidents, Aviation | 1 | 1994 | 4 | 0.120 |
Why?
| | Neoplasm Invasiveness | 6 | 2014 | 442 | 0.120 |
Why?
| | Olfactory Pathways | 1 | 2015 | 56 | 0.120 |
Why?
| | Karyotyping | 3 | 2008 | 102 | 0.120 |
Why?
| | Orbit | 1 | 2015 | 59 | 0.120 |
Why?
| | Cranial Irradiation | 1 | 1995 | 66 | 0.120 |
Why?
| | Child | 9 | 2022 | 18412 | 0.120 |
Why?
| | Acromegaly | 1 | 2014 | 12 | 0.120 |
Why?
| | Seizures | 1 | 2017 | 340 | 0.120 |
Why?
| | Spinal Cord Neoplasms | 1 | 2014 | 37 | 0.120 |
Why?
| | Intervertebral Disc Displacement | 2 | 1998 | 36 | 0.120 |
Why?
| | Human Growth Hormone | 1 | 2014 | 38 | 0.120 |
Why?
| | Cadherins | 1 | 2015 | 175 | 0.120 |
Why?
| | ACTH-Secreting Pituitary Adenoma | 1 | 2014 | 6 | 0.120 |
Why?
| | Ganglioglioma | 1 | 2014 | 31 | 0.110 |
Why?
| | Gene Expression Profiling | 4 | 2020 | 1518 | 0.110 |
Why?
| | Orbital Neoplasms | 1 | 2014 | 21 | 0.110 |
Why?
| | Immune Tolerance | 2 | 2008 | 323 | 0.110 |
Why?
| | Cerebral Hemorrhage | 2 | 1985 | 96 | 0.110 |
Why?
| | Pituitary Gland, Posterior | 1 | 2013 | 2 | 0.110 |
Why?
| | Ganglioneuroma | 1 | 2013 | 2 | 0.110 |
Why?
| | Sarcoma, Alveolar Soft Part | 1 | 1993 | 7 | 0.110 |
Why?
| | Telomerase | 3 | 2003 | 206 | 0.110 |
Why?
| | Aspergillosis | 1 | 2013 | 23 | 0.110 |
Why?
| | Adenocarcinoma, Bronchiolo-Alveolar | 1 | 2013 | 19 | 0.110 |
Why?
| | Joint Dislocations | 1 | 1993 | 57 | 0.110 |
Why?
| | Patient Readmission | 1 | 2018 | 610 | 0.110 |
Why?
| | Dog Diseases | 1 | 2013 | 41 | 0.110 |
Why?
| | Spinal Injuries | 1 | 1993 | 47 | 0.100 |
Why?
| | Neoplasm Transplantation | 3 | 2000 | 228 | 0.100 |
Why?
| | Soft Tissue Neoplasms | 1 | 1993 | 90 | 0.100 |
Why?
| | Curriculum | 1 | 2018 | 819 | 0.100 |
Why?
| | Polymerase Chain Reaction | 4 | 2012 | 993 | 0.100 |
Why?
| | Immunoglobulin Heavy Chains | 2 | 2009 | 72 | 0.100 |
Why?
| | Muscles | 1 | 1993 | 320 | 0.100 |
Why?
| | Craniotomy | 3 | 2015 | 68 | 0.100 |
Why?
| | Isocitrate Dehydrogenase | 1 | 2012 | 38 | 0.100 |
Why?
| | Spine | 1 | 1993 | 136 | 0.100 |
Why?
| | Research Design | 1 | 2017 | 928 | 0.100 |
Why?
| | Skull | 2 | 2007 | 119 | 0.100 |
Why?
| | Cell Division | 4 | 2012 | 758 | 0.090 |
Why?
| | Severity of Illness Index | 1 | 2019 | 2538 | 0.090 |
Why?
| | Antigens, Differentiation | 1 | 2011 | 79 | 0.090 |
Why?
| | Mitotic Index | 2 | 2011 | 26 | 0.090 |
Why?
| | Fibrous Dysplasia, Polyostotic | 1 | 2010 | 7 | 0.090 |
Why?
| | Animals | 14 | 2013 | 31698 | 0.090 |
Why?
| | Adenoma, Oxyphilic | 1 | 2010 | 5 | 0.090 |
Why?
| | Tumor Burden | 4 | 2012 | 259 | 0.090 |
Why?
| | SMARCB1 Protein | 1 | 2010 | 17 | 0.090 |
Why?
| | Registries | 1 | 2017 | 1768 | 0.090 |
Why?
| | Claudins | 1 | 2010 | 24 | 0.090 |
Why?
| | Lymphoma | 2 | 2008 | 177 | 0.090 |
Why?
| | Gene Rearrangement, B-Lymphocyte, Heavy Chain | 1 | 2009 | 12 | 0.080 |
Why?
| | Tanzania | 2 | 2020 | 41 | 0.080 |
Why?
| | Proteome | 1 | 2013 | 339 | 0.080 |
Why?
| | Immunity, Cellular | 2 | 2003 | 248 | 0.080 |
Why?
| | Piperidines | 1 | 2010 | 160 | 0.080 |
Why?
| | Internship and Residency | 1 | 2018 | 926 | 0.080 |
Why?
| | Tumor Suppressor Proteins | 1 | 2011 | 282 | 0.080 |
Why?
| | Neuroaspergillosis | 1 | 2008 | 2 | 0.080 |
Why?
| | Brain Abscess | 1 | 2008 | 11 | 0.080 |
Why?
| | Killer Cells, Lymphokine-Activated | 4 | 1993 | 9 | 0.080 |
Why?
| | Genetic Vectors | 2 | 2008 | 289 | 0.080 |
Why?
| | Cytogenetics | 1 | 2008 | 11 | 0.080 |
Why?
| | Dogs | 2 | 2013 | 334 | 0.080 |
Why?
| | Cell Cycle Proteins | 1 | 2012 | 551 | 0.080 |
Why?
| | Arm Injuries | 1 | 1988 | 23 | 0.080 |
Why?
| | Cytotoxicity, Immunologic | 3 | 2006 | 195 | 0.080 |
Why?
| | Prolactin | 3 | 2019 | 96 | 0.080 |
Why?
| | Child, Preschool | 5 | 2017 | 9114 | 0.070 |
Why?
| | Superoxide Dismutase | 2 | 2000 | 305 | 0.070 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2008 | 72 | 0.070 |
Why?
| | Radiotherapy Dosage | 3 | 2010 | 244 | 0.070 |
Why?
| | Drug Administration Schedule | 3 | 2010 | 718 | 0.070 |
Why?
| | Interferon-beta | 1 | 2008 | 79 | 0.070 |
Why?
| | Wounds, Penetrating | 1 | 1988 | 73 | 0.070 |
Why?
| | Nerve Sheath Neoplasms | 1 | 2007 | 7 | 0.070 |
Why?
| | Mesenchymoma | 1 | 2007 | 7 | 0.070 |
Why?
| | Hematoma | 2 | 1985 | 49 | 0.070 |
Why?
| | Neoplasm Staging | 4 | 2015 | 1167 | 0.070 |
Why?
| | Carcinoma, Adenoid Cystic | 1 | 2007 | 17 | 0.070 |
Why?
| | Multiple Sclerosis | 1 | 2012 | 376 | 0.070 |
Why?
| | Wounds and Injuries | 1 | 1994 | 749 | 0.070 |
Why?
| | Adenoviridae | 1 | 2008 | 184 | 0.070 |
Why?
| | Scalp | 1 | 2007 | 29 | 0.070 |
Why?
| | Neoplastic Syndromes, Hereditary | 1 | 2007 | 30 | 0.070 |
Why?
| | Cell Survival | 4 | 2015 | 1021 | 0.070 |
Why?
| | Radiography | 3 | 2013 | 812 | 0.070 |
Why?
| | Dexamethasone | 4 | 2012 | 317 | 0.070 |
Why?
| | Blood Vessels | 1 | 1988 | 180 | 0.070 |
Why?
| | Vaccination | 2 | 2023 | 1204 | 0.070 |
Why?
| | Enophthalmos | 1 | 2006 | 1 | 0.070 |
Why?
| | Blepharoptosis | 1 | 2006 | 6 | 0.070 |
Why?
| | Base Pair Mismatch | 1 | 2006 | 14 | 0.070 |
Why?
| | Hemangioma, Capillary | 1 | 2006 | 13 | 0.070 |
Why?
| | Injections, Subcutaneous | 1 | 2006 | 134 | 0.070 |
Why?
| | Epidermal Cyst | 1 | 2006 | 12 | 0.070 |
Why?
| | Imatinib Mesylate | 1 | 2006 | 63 | 0.070 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2008 | 386 | 0.070 |
Why?
| | Immunoprecipitation | 1 | 2006 | 151 | 0.070 |
Why?
| | Parietal Lobe | 1 | 2006 | 41 | 0.070 |
Why?
| | Teratoma | 1 | 2007 | 92 | 0.070 |
Why?
| | Genetic Therapy | 1 | 2008 | 257 | 0.070 |
Why?
| | Lymphoma, Follicular | 1 | 2006 | 35 | 0.070 |
Why?
| | Chest Pain | 1 | 2006 | 81 | 0.060 |
Why?
| | Brain Edema | 2 | 2004 | 60 | 0.060 |
Why?
| | Disease Models, Animal | 2 | 2006 | 3532 | 0.060 |
Why?
| | Cell Line, Tumor | 3 | 2015 | 2710 | 0.060 |
Why?
| | Neoplasm, Residual | 2 | 2020 | 104 | 0.060 |
Why?
| | Databases, Factual | 1 | 2010 | 1125 | 0.060 |
Why?
| | Karnofsky Performance Status | 3 | 2013 | 36 | 0.060 |
Why?
| | Bone Diseases | 1 | 2006 | 57 | 0.060 |
Why?
| | Benzamides | 1 | 2006 | 169 | 0.060 |
Why?
| | United States | 3 | 2017 | 12181 | 0.060 |
Why?
| | Ultrasonics | 2 | 2002 | 46 | 0.060 |
Why?
| | Wounds, Nonpenetrating | 1 | 1988 | 256 | 0.060 |
Why?
| | Exons | 1 | 2006 | 302 | 0.060 |
Why?
| | Lymphoma, B-Cell | 1 | 2006 | 86 | 0.060 |
Why?
| | Maximum Tolerated Dose | 3 | 2010 | 183 | 0.060 |
Why?
| | Medulloblastoma | 1 | 2007 | 172 | 0.060 |
Why?
| | Predictive Value of Tests | 1 | 2010 | 1796 | 0.060 |
Why?
| | Myelography | 2 | 2022 | 19 | 0.060 |
Why?
| | Cushing Syndrome | 1 | 2004 | 10 | 0.060 |
Why?
| | Brain | 6 | 2017 | 2371 | 0.060 |
Why?
| | Calcitonin | 1 | 2004 | 23 | 0.060 |
Why?
| | Bevacizumab | 2 | 2015 | 115 | 0.060 |
Why?
| | Subarachnoid Space | 1 | 2004 | 8 | 0.060 |
Why?
| | Quality of Life | 2 | 2013 | 2353 | 0.060 |
Why?
| | von Hippel-Lindau Disease | 1 | 2004 | 11 | 0.060 |
Why?
| | S100 Proteins | 2 | 1995 | 38 | 0.060 |
Why?
| | Piperazines | 1 | 2006 | 309 | 0.060 |
Why?
| | Craniocerebral Trauma | 1 | 1985 | 134 | 0.060 |
Why?
| | Radiotherapy | 1 | 2004 | 176 | 0.060 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 4 | 2011 | 923 | 0.060 |
Why?
| | Cranial Fossa, Posterior | 2 | 2012 | 16 | 0.060 |
Why?
| | Neoplasms, Neuroepithelial | 1 | 2003 | 17 | 0.050 |
Why?
| | Lymphocyte Activation | 3 | 1993 | 1037 | 0.050 |
Why?
| | Disease Progression | 2 | 2021 | 2380 | 0.050 |
Why?
| | Age Factors | 4 | 2014 | 2894 | 0.050 |
Why?
| | Incidence | 3 | 2003 | 2313 | 0.050 |
Why?
| | Pyrimidines | 1 | 2006 | 376 | 0.050 |
Why?
| | Polymers | 2 | 1997 | 448 | 0.050 |
Why?
| | Nerve Tissue Proteins | 1 | 2006 | 529 | 0.050 |
Why?
| | Image Enhancement | 1 | 2004 | 159 | 0.050 |
Why?
| | Dura Mater | 2 | 2000 | 27 | 0.050 |
Why?
| | Hydrocortisone | 1 | 2004 | 267 | 0.050 |
Why?
| | Neoplasm Proteins | 2 | 2003 | 384 | 0.050 |
Why?
| | Cell Movement | 1 | 2006 | 868 | 0.050 |
Why?
| | Case-Control Studies | 2 | 2021 | 3003 | 0.050 |
Why?
| | Transferases | 1 | 2022 | 28 | 0.050 |
Why?
| | Microtubule-Associated Proteins | 1 | 2003 | 174 | 0.050 |
Why?
| | Cerebrospinal Fluid Leak | 1 | 2022 | 28 | 0.050 |
Why?
| | Drug Resistance, Multiple | 1 | 2001 | 19 | 0.050 |
Why?
| | Hyperthermia, Induced | 1 | 2002 | 65 | 0.050 |
Why?
| | DNA, Neoplasm | 3 | 2005 | 157 | 0.050 |
Why?
| | Spinal Cord | 1 | 2004 | 347 | 0.050 |
Why?
| | Thyrotropin | 5 | 1999 | 99 | 0.050 |
Why?
| | Public Opinion | 1 | 2021 | 59 | 0.050 |
Why?
| | Immunosuppressive Agents | 2 | 2008 | 646 | 0.050 |
Why?
| | Neuroimmunomodulation | 1 | 2000 | 70 | 0.040 |
Why?
| | Gene Amplification | 2 | 2015 | 95 | 0.040 |
Why?
| | Surgical Wound Infection | 1 | 2003 | 248 | 0.040 |
Why?
| | Vulnerable Populations | 1 | 2021 | 133 | 0.040 |
Why?
| | Ethmoid Sinus | 1 | 2000 | 7 | 0.040 |
Why?
| | Frontal Sinus | 1 | 2000 | 4 | 0.040 |
Why?
| | Visual Fields | 1 | 2020 | 77 | 0.040 |
Why?
| | Infant | 2 | 2008 | 7961 | 0.040 |
Why?
| | Arginine Vasopressin | 1 | 2000 | 46 | 0.040 |
Why?
| | Free Radicals | 1 | 2000 | 99 | 0.040 |
Why?
| | Hot Temperature | 1 | 2001 | 302 | 0.040 |
Why?
| | Depressive Disorder, Major | 1 | 2003 | 301 | 0.040 |
Why?
| | Pituitary Hormones | 1 | 1999 | 16 | 0.040 |
Why?
| | Recurrence | 1 | 2023 | 935 | 0.040 |
Why?
| | Skin Neoplasms | 1 | 2007 | 756 | 0.040 |
Why?
| | Cerebral Cortex | 2 | 1998 | 380 | 0.040 |
Why?
| | Dopamine Agonists | 1 | 2019 | 32 | 0.040 |
Why?
| | Gonadotropins, Pituitary | 2 | 2008 | 22 | 0.040 |
Why?
| | Drug Delivery Systems | 1 | 2002 | 296 | 0.040 |
Why?
| | Chromosomes, Human, Pair 7 | 2 | 2005 | 15 | 0.040 |
Why?
| | Up-Regulation | 2 | 2015 | 807 | 0.040 |
Why?
| | Apoptosis | 2 | 2015 | 2362 | 0.040 |
Why?
| | Injections, Intralesional | 1 | 1998 | 32 | 0.040 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2003 | 636 | 0.040 |
Why?
| | Cerebral Veins | 1 | 1998 | 15 | 0.040 |
Why?
| | Visual Acuity | 1 | 2020 | 274 | 0.040 |
Why?
| | Biopsy | 2 | 2017 | 1036 | 0.040 |
Why?
| | Smooth Muscle Tumor | 1 | 1998 | 6 | 0.040 |
Why?
| | Sarcoma, Synovial | 1 | 1998 | 11 | 0.040 |
Why?
| | Catheters, Indwelling | 1 | 1998 | 79 | 0.040 |
Why?
| | Capacity Building | 1 | 2018 | 51 | 0.040 |
Why?
| | Leiomyosarcoma | 1 | 1998 | 26 | 0.040 |
Why?
| | Tertiary Care Centers | 1 | 2018 | 126 | 0.040 |
Why?
| | Preoperative Care | 2 | 2003 | 319 | 0.040 |
Why?
| | Endpoint Determination | 1 | 2018 | 68 | 0.040 |
Why?
| | Drug Synergism | 1 | 1998 | 316 | 0.040 |
Why?
| | Meningomyelocele | 1 | 1998 | 55 | 0.040 |
Why?
| | DNA Methylation | 1 | 2022 | 495 | 0.040 |
Why?
| | Cell Line | 3 | 2012 | 2636 | 0.040 |
Why?
| | Leiomyoma | 1 | 1998 | 44 | 0.040 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2000 | 308 | 0.040 |
Why?
| | Brain Diseases | 2 | 1998 | 125 | 0.040 |
Why?
| | Hypophysitis | 1 | 2017 | 2 | 0.040 |
Why?
| | Hydrocephalus | 2 | 2017 | 83 | 0.040 |
Why?
| | Neuroectodermal Tumors, Primitive | 1 | 1997 | 12 | 0.040 |
Why?
| | Interferon-gamma | 1 | 2000 | 719 | 0.040 |
Why?
| | Ventriculostomy | 1 | 2017 | 17 | 0.040 |
Why?
| | Neuroendoscopy | 1 | 2017 | 14 | 0.040 |
Why?
| | Premenopause | 1 | 2017 | 106 | 0.040 |
Why?
| | RNA, Messenger | 5 | 2011 | 2552 | 0.040 |
Why?
| | Developing Countries | 1 | 2018 | 235 | 0.030 |
Why?
| | Gonadotropins | 2 | 1999 | 37 | 0.030 |
Why?
| | Microarray Analysis | 1 | 2017 | 118 | 0.030 |
Why?
| | Postoperative Care | 1 | 1998 | 222 | 0.030 |
Why?
| | Injections, Intraperitoneal | 1 | 1996 | 99 | 0.030 |
Why?
| | Granuloma | 1 | 2017 | 83 | 0.030 |
Why?
| | Immunoenzyme Techniques | 2 | 2012 | 192 | 0.030 |
Why?
| | Cerebrospinal Fluid | 1 | 2017 | 90 | 0.030 |
Why?
| | Immunophenotyping | 1 | 1997 | 274 | 0.030 |
Why?
| | Biodegradation, Environmental | 1 | 1996 | 80 | 0.030 |
Why?
| | Practice Patterns, Physicians' | 1 | 2005 | 1177 | 0.030 |
Why?
| | Endoscopy | 1 | 2018 | 246 | 0.030 |
Why?
| | Signal Transduction | 3 | 2015 | 4512 | 0.030 |
Why?
| | Drainage | 1 | 2017 | 151 | 0.030 |
Why?
| | Delayed-Action Preparations | 1 | 1997 | 159 | 0.030 |
Why?
| | Cognition Disorders | 2 | 2015 | 476 | 0.030 |
Why?
| | Intraoperative Complications | 1 | 2017 | 122 | 0.030 |
Why?
| | Computational Biology | 1 | 2020 | 530 | 0.030 |
Why?
| | Endothelium, Vascular | 1 | 2002 | 847 | 0.030 |
Why?
| | Faculty, Medical | 1 | 2018 | 228 | 0.030 |
Why?
| | Hyperostosis | 1 | 1995 | 5 | 0.030 |
Why?
| | Diagnostic Imaging | 1 | 1998 | 275 | 0.030 |
Why?
| | Olfactory Nerve | 1 | 2015 | 9 | 0.030 |
Why?
| | Anticonvulsants | 1 | 2017 | 179 | 0.030 |
Why?
| | Colorado | 2 | 2018 | 4099 | 0.030 |
Why?
| | Lactic Acid | 1 | 1997 | 275 | 0.030 |
Why?
| | Cells, Cultured | 3 | 2006 | 3885 | 0.030 |
Why?
| | DNA | 1 | 2022 | 1352 | 0.030 |
Why?
| | Cysticercosis | 1 | 1995 | 3 | 0.030 |
Why?
| | Tumor Stem Cell Assay | 1 | 2015 | 33 | 0.030 |
Why?
| | Audiometry | 1 | 1995 | 30 | 0.030 |
Why?
| | Cytoprotection | 1 | 2015 | 51 | 0.030 |
Why?
| | Neural Cell Adhesion Molecules | 1 | 1995 | 24 | 0.030 |
Why?
| | Nasal Cavity | 1 | 2015 | 47 | 0.030 |
Why?
| | Neuropsychological Tests | 2 | 2013 | 927 | 0.030 |
Why?
| | Cerebral Infarction | 1 | 1995 | 39 | 0.030 |
Why?
| | Seat Belts | 1 | 1994 | 18 | 0.030 |
Why?
| | Cerebral Arteries | 1 | 2015 | 55 | 0.030 |
Why?
| | Gait Disorders, Neurologic | 1 | 2015 | 41 | 0.030 |
Why?
| | Mutant Proteins | 1 | 2015 | 95 | 0.030 |
Why?
| | Recombinant Proteins | 3 | 1993 | 1230 | 0.030 |
Why?
| | Cerebral Angiography | 1 | 1995 | 109 | 0.030 |
Why?
| | Aircraft | 1 | 1994 | 26 | 0.030 |
Why?
| | Marital Status | 1 | 2014 | 41 | 0.030 |
Why?
| | Personality Disorders | 1 | 2015 | 67 | 0.030 |
Why?
| | Cohort Studies | 2 | 2017 | 4895 | 0.030 |
Why?
| | Neuroimaging | 1 | 2016 | 249 | 0.030 |
Why?
| | Image Processing, Computer-Assisted | 1 | 1998 | 683 | 0.030 |
Why?
| | Computer Simulation | 1 | 1998 | 872 | 0.030 |
Why?
| | DNA Copy Number Variations | 1 | 2015 | 154 | 0.030 |
Why?
| | Minimally Invasive Surgical Procedures | 1 | 2015 | 154 | 0.030 |
Why?
| | Cell Hypoxia | 1 | 2015 | 220 | 0.030 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 1 | 2015 | 260 | 0.030 |
Why?
| | Mice | 4 | 2012 | 14863 | 0.030 |
Why?
| | SEER Program | 1 | 2014 | 196 | 0.030 |
Why?
| | Paresis | 2 | 2007 | 28 | 0.030 |
Why?
| | Nervous System | 1 | 1993 | 63 | 0.030 |
Why?
| | Hypothyroidism | 2 | 1992 | 64 | 0.030 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2015 | 249 | 0.030 |
Why?
| | Models, Biological | 1 | 2000 | 1620 | 0.030 |
Why?
| | Antibodies, Monoclonal | 4 | 2008 | 1262 | 0.030 |
Why?
| | Chronic Disease | 1 | 2018 | 1578 | 0.030 |
Why?
| | Neuroblastoma | 1 | 1993 | 133 | 0.030 |
Why?
| | Reproducibility of Results | 1 | 2020 | 2763 | 0.030 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2015 | 398 | 0.030 |
Why?
| | Safety | 1 | 1994 | 297 | 0.030 |
Why?
| | Phosphopyruvate Hydratase | 1 | 1992 | 30 | 0.030 |
Why?
| | Dose-Response Relationship, Drug | 1 | 1996 | 1842 | 0.030 |
Why?
| | Cyclophosphamide | 1 | 1993 | 217 | 0.030 |
Why?
| | Protein Structure, Tertiary | 1 | 2015 | 796 | 0.030 |
Why?
| | Fatal Outcome | 2 | 2007 | 284 | 0.030 |
Why?
| | Vimentin | 1 | 1992 | 58 | 0.030 |
Why?
| | Drug Screening Assays, Antitumor | 1 | 1993 | 180 | 0.030 |
Why?
| | G2 Phase | 1 | 2012 | 31 | 0.030 |
Why?
| | Lymphocytosis | 1 | 1992 | 9 | 0.020 |
Why?
| | Lymphocytes | 1 | 1993 | 330 | 0.020 |
Why?
| | CpG Islands | 1 | 2012 | 117 | 0.020 |
Why?
| | Active Transport, Cell Nucleus | 1 | 2012 | 110 | 0.020 |
Why?
| | Stress, Physiological | 1 | 2015 | 378 | 0.020 |
Why?
| | Cavernous Sinus | 1 | 2011 | 14 | 0.020 |
Why?
| | Analysis of Variance | 1 | 2014 | 1226 | 0.020 |
Why?
| | Cytoplasm | 1 | 2012 | 255 | 0.020 |
Why?
| | Skull Base | 1 | 2011 | 39 | 0.020 |
Why?
| | Recovery of Function | 1 | 2015 | 574 | 0.020 |
Why?
| | Algorithms | 1 | 1998 | 1468 | 0.020 |
Why?
| | PTEN Phosphohydrolase | 1 | 2012 | 140 | 0.020 |
Why?
| | Intraoperative Care | 2 | 2003 | 34 | 0.020 |
Why?
| | Cytotoxicity Tests, Immunologic | 1 | 1991 | 43 | 0.020 |
Why?
| | Spleen | 1 | 1993 | 487 | 0.020 |
Why?
| | Green Fluorescent Proteins | 1 | 2012 | 371 | 0.020 |
Why?
| | Carcinoma | 1 | 2012 | 198 | 0.020 |
Why?
| | Retreatment | 1 | 2010 | 67 | 0.020 |
Why?
| | Vincristine | 1 | 2010 | 98 | 0.020 |
Why?
| | Carboplatin | 1 | 2010 | 135 | 0.020 |
Why?
| | T-Lymphocytes, Regulatory | 1 | 1993 | 339 | 0.020 |
Why?
| | Camptothecin | 1 | 2010 | 96 | 0.020 |
Why?
| | Vision Disorders | 2 | 2007 | 130 | 0.020 |
Why?
| | Microscopy, Electron, Transmission | 1 | 2010 | 135 | 0.020 |
Why?
| | Ultrasonography | 2 | 1984 | 634 | 0.020 |
Why?
| | Necrosis | 1 | 2010 | 211 | 0.020 |
Why?
| | Salvage Therapy | 1 | 2010 | 127 | 0.020 |
Why?
| | Hypogonadism | 1 | 1990 | 75 | 0.020 |
Why?
| | Sex Factors | 1 | 2014 | 1715 | 0.020 |
Why?
| | Follicle Stimulating Hormone | 3 | 1999 | 216 | 0.020 |
Why?
| | Infant, Newborn | 3 | 1997 | 5045 | 0.020 |
Why?
| | DNA Damage | 1 | 2011 | 351 | 0.020 |
Why?
| | Kinetics | 1 | 1992 | 1551 | 0.020 |
Why?
| | Tomography Scanners, X-Ray Computed | 1 | 2008 | 17 | 0.020 |
Why?
| | Antigens, CD20 | 1 | 2008 | 27 | 0.020 |
Why?
| | Axillary Artery | 1 | 1988 | 12 | 0.020 |
Why?
| | Autoimmune Diseases | 1 | 1992 | 382 | 0.020 |
Why?
| | Anti-Inflammatory Agents | 1 | 2012 | 447 | 0.020 |
Why?
| | CD3 Complex | 1 | 2008 | 92 | 0.020 |
Why?
| | Antibodies, Monoclonal, Murine-Derived | 1 | 2008 | 82 | 0.020 |
Why?
| | Subclavian Artery | 1 | 1988 | 29 | 0.020 |
Why?
| | Administration, Oral | 1 | 2010 | 728 | 0.020 |
Why?
| | Risk Assessment | 1 | 2017 | 2968 | 0.020 |
Why?
| | Linear Models | 1 | 2010 | 768 | 0.020 |
Why?
| | Mental Status Schedule | 1 | 2007 | 33 | 0.020 |
Why?
| | Rituximab | 1 | 2008 | 150 | 0.020 |
Why?
| | Promoter Regions, Genetic | 1 | 2012 | 1131 | 0.020 |
Why?
| | Methotrexate | 1 | 2008 | 226 | 0.020 |
Why?
| | Proteomics | 1 | 2013 | 836 | 0.020 |
Why?
| | Proportional Hazards Models | 1 | 2010 | 1075 | 0.020 |
Why?
| | Pregnancy Complications | 1 | 1992 | 429 | 0.020 |
Why?
| | DNA Primers | 2 | 1999 | 510 | 0.020 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2008 | 351 | 0.020 |
Why?
| | Microscopy, Electron | 1 | 2007 | 410 | 0.020 |
Why?
| | In Vitro Techniques | 2 | 1989 | 1016 | 0.020 |
Why?
| | Multigene Family | 1 | 2007 | 190 | 0.020 |
Why?
| | Glucocorticoids | 1 | 2010 | 532 | 0.020 |
Why?
| | Cognition | 1 | 2013 | 989 | 0.020 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2008 | 367 | 0.020 |
Why?
| | Bone Morphogenetic Proteins | 1 | 2006 | 132 | 0.020 |
Why?
| | Tretinoin | 1 | 2006 | 122 | 0.020 |
Why?
| | Interleukin-10 | 1 | 2008 | 299 | 0.020 |
Why?
| | Coma | 1 | 1985 | 30 | 0.020 |
Why?
| | Athletic Injuries | 1 | 1991 | 456 | 0.020 |
Why?
| | Action Potentials | 1 | 1988 | 406 | 0.020 |
Why?
| | Data Interpretation, Statistical | 1 | 2007 | 321 | 0.020 |
Why?
| | Intracranial Pressure | 1 | 1985 | 48 | 0.020 |
Why?
| | Prostatic Neoplasms | 1 | 2012 | 921 | 0.010 |
Why?
| | Blood-Brain Barrier | 1 | 1985 | 106 | 0.010 |
Why?
| | Brain Concussion | 1 | 1991 | 476 | 0.010 |
Why?
| | Interleukin-6 | 1 | 2008 | 676 | 0.010 |
Why?
| | Citrates | 1 | 1984 | 43 | 0.010 |
Why?
| | Genetic Predisposition to Disease | 1 | 2012 | 2085 | 0.010 |
Why?
| | Antigens, CD | 1 | 2006 | 442 | 0.010 |
Why?
| | Sound | 1 | 1984 | 65 | 0.010 |
Why?
| | Blood | 1 | 1984 | 96 | 0.010 |
Why?
| | Inhibitor of Apoptosis Proteins | 1 | 2003 | 42 | 0.010 |
Why?
| | Injections | 1 | 1984 | 159 | 0.010 |
Why?
| | Trauma Centers | 1 | 1985 | 362 | 0.010 |
Why?
| | Heparin | 1 | 1984 | 224 | 0.010 |
Why?
| | Rhodamine 123 | 1 | 2001 | 3 | 0.010 |
Why?
| | Microcirculation | 1 | 2002 | 135 | 0.010 |
Why?
| | Biological Transport, Active | 1 | 2001 | 71 | 0.010 |
Why?
| | Cyclosporins | 1 | 2001 | 58 | 0.010 |
Why?
| | Pulsatile Flow | 2 | 1991 | 54 | 0.010 |
Why?
| | Gene Expression | 1 | 2006 | 1421 | 0.010 |
Why?
| | Respiration, Artificial | 1 | 1985 | 529 | 0.010 |
Why?
| | Lung | 1 | 2013 | 3559 | 0.010 |
Why?
| | Doxorubicin | 1 | 2001 | 285 | 0.010 |
Why?
| | Luteinizing Hormone | 2 | 1991 | 169 | 0.010 |
Why?
| | Fushi Tarazu Transcription Factors | 1 | 1999 | 5 | 0.010 |
Why?
| | Steroidogenic Factor 1 | 1 | 1999 | 6 | 0.010 |
Why?
| | Transcription Factor Pit-1 | 1 | 1999 | 24 | 0.010 |
Why?
| | Cattle | 1 | 2002 | 920 | 0.010 |
Why?
| | Amino Acid Sequence | 1 | 2003 | 1982 | 0.010 |
Why?
| | Brown-Sequard Syndrome | 1 | 1998 | 5 | 0.010 |
Why?
| | Syringomyelia | 1 | 1998 | 11 | 0.010 |
Why?
| | Molecular Sequence Data | 1 | 2003 | 2785 | 0.010 |
Why?
| | Pyramidal Tracts | 1 | 1998 | 20 | 0.010 |
Why?
| | Sensation Disorders | 1 | 1998 | 31 | 0.010 |
Why?
| | Thoracic Vertebrae | 1 | 1998 | 68 | 0.010 |
Why?
| | Iatrogenic Disease | 1 | 1998 | 49 | 0.010 |
Why?
| | Therapy, Computer-Assisted | 1 | 1998 | 58 | 0.010 |
Why?
| | Receptors, Cytoplasmic and Nuclear | 1 | 1999 | 192 | 0.010 |
Why?
| | Photography | 1 | 1998 | 89 | 0.010 |
Why?
| | Tumor Virus Infections | 1 | 1998 | 43 | 0.010 |
Why?
| | Immunologic Deficiency Syndromes | 1 | 1998 | 61 | 0.010 |
Why?
| | Cervical Vertebrae | 1 | 1998 | 100 | 0.010 |
Why?
| | Mice, Inbred C57BL | 1 | 2006 | 4692 | 0.010 |
Why?
| | Herpesvirus 4, Human | 1 | 1998 | 125 | 0.010 |
Why?
| | Spinal Fractures | 1 | 1998 | 75 | 0.010 |
Why?
| | Herpesviridae Infections | 1 | 1998 | 138 | 0.010 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 1997 | 318 | 0.010 |
Why?
| | Lumbar Vertebrae | 1 | 1998 | 209 | 0.010 |
Why?
| | Acquired Immunodeficiency Syndrome | 1 | 1998 | 217 | 0.010 |
Why?
| | Homeodomain Proteins | 1 | 1999 | 463 | 0.010 |
Why?
| | Spinal Cord Injuries | 1 | 1998 | 174 | 0.010 |
Why?
| | Praziquantel | 1 | 1995 | 5 | 0.010 |
Why?
| | Ventriculoperitoneal Shunt | 1 | 1995 | 31 | 0.010 |
Why?
| | RNA, Viral | 1 | 1998 | 565 | 0.010 |
Why?
| | Carotid Stenosis | 1 | 1995 | 79 | 0.010 |
Why?
| | Sensitivity and Specificity | 1 | 1998 | 1692 | 0.010 |
Why?
| | Optic Chiasm | 1 | 1992 | 18 | 0.010 |
Why?
| | Nerve Compression Syndromes | 1 | 1992 | 25 | 0.010 |
Why?
| | Unconsciousness | 1 | 1991 | 18 | 0.010 |
Why?
| | Amnesia | 1 | 1991 | 42 | 0.010 |
Why?
| | Surveys and Questionnaires | 1 | 2003 | 4622 | 0.010 |
Why?
| | Osmolar Concentration | 1 | 1991 | 173 | 0.010 |
Why?
| | Pregnancy Complications, Neoplastic | 1 | 1992 | 50 | 0.010 |
Why?
| | Headache | 1 | 1992 | 133 | 0.010 |
Why?
| | Football | 1 | 1991 | 76 | 0.010 |
Why?
| | Immunochemistry | 1 | 1989 | 11 | 0.010 |
Why?
| | Autoradiography | 1 | 1989 | 70 | 0.010 |
Why?
| | Hyperthyroidism | 1 | 1989 | 26 | 0.010 |
Why?
| | Histocytochemistry | 1 | 1989 | 78 | 0.010 |
Why?
| | Circadian Rhythm | 1 | 1991 | 354 | 0.000 |
Why?
| | Neutrophils | 1 | 1989 | 1176 | 0.000 |
Why?
| | Transcription, Genetic | 1 | 1989 | 1313 | 0.000 |
Why?
| | Intraoperative Period | 1 | 1982 | 51 | 0.000 |
Why?
| | Arteriovenous Malformations | 1 | 1982 | 24 | 0.000 |
Why?
| | Cerebrospinal Fluid Shunts | 1 | 1982 | 28 | 0.000 |
Why?
| | T-Lymphocytes | 1 | 1989 | 1737 | 0.000 |
Why?
| | Phenotype | 1 | 1989 | 2796 | 0.000 |
Why?
| | Pregnancy | 1 | 1992 | 5518 | 0.000 |
Why?
| | Gene Expression Regulation | 1 | 1989 | 2319 | 0.000 |
Why?
|
|
Lillehei's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|